Icecure Medical Ltd ICCM.OQ ICCM.O is expected to show a rise in quarterly revenue when it reports results on March 3 (estimated) for the period ending December 31 2025
The Caesarea Israel-based company is expected to report a 117.1% increase in revenue to $1.9 million from $875 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Icecure Medical Ltd is for a loss of 4 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Icecure Medical Ltd is $3.13, about 428% above its last closing price of $0.59
This summary was machine generated February 27 at 13:47 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments